Literature DB >> 30227225

Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup.

Vishvanath Tiwari1, Kiran Meena2, Monalisa Tiwari2.   

Abstract

Nosocomial infections are caused by ESKAPE (E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae) pathogens, and their co-existence is associated with their ability to survive in the hospital setup. They may produce molecules, which helps in the better survival of one ESKAPE pathogens over other. We have identified all secondary metabolite gene clusters in six ESKAPE pathogens and predicted antimicrobial and anti-biofilm properties of their product secondary metabolites. To validate our model, we have taken the secondary metabolites of ESKAPE pathogens and studied their interaction with diguanylate cyclase (involved in quorum sensing) and biofilm-associated protein (involved in biofilm formation) of Acinetobacter baumannii. Results suggest the presence of differential secondary metabolites in all ESKAPE pathogens with only three common non-antimicrobial secondary metabolites. Out of twenty-three antimicrobial secondary metabolites, TP-1161, nosiheptide and meilingmycin, showed the best antimicrobial activity and nineteen showed high anti-biofilm activity. Interaction study showed that secondary metabolites produced by other ESKAPE pathogens (non-Acinetobacter) have very good interaction with diguanylate cyclase and biofilm-associated protein of A. baumannii. This concludes that better survival of these ESKAPE pathogens in hospital setup can be correlated with differential production of antimicrobial secondary metabolites. The present study also investigates the molecular mechanism of the competition of different pathogens living in similar hospital setup (similar habitat). Therefore, the present study will initiate research that might lead to the discovery of antibiotics from one ESKAPE pathogen that controls the infection of other ESKAPE pathogens or other pathogens.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-biofilm; Anti-microbial Secondary Metabolite; Drug Resistance; ESKAPE pathogens; Nosocomial infections; Secondary Metabolite Gene Clusters

Mesh:

Substances:

Year:  2018        PMID: 30227225     DOI: 10.1016/j.meegid.2018.09.010

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  6 in total

1.  Inosine and D-Mannose Secreted by Drug-Resistant Klebsiella pneumoniae Affect Viability of Lung Epithelial Cells.

Authors:  Yuhan Zhang; Ziwei Zhou; Wenxuan Xiao; Yuting Tang; Wei Guan; Jiang Wang; Farui Shu; Jiaqi Shen; Shaoyan Gu; Lu Zhang; Qingzhong Wang; Lixin Xie
Journal:  Molecules       Date:  2022-05-06       Impact factor: 4.927

2.  Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus.

Authors:  Vishvanath Tiwari
Journal:  Int J Biol Macromol       Date:  2021-01-07       Impact factor: 6.953

3.  Antibacterial and antitumor activities of a lectin-rich preparation from Microgramma vacciniifolia rhizome.

Authors:  Gabriela Cavalcante da Silva; Alisson Macário de Oliveira; Wêndeo Kennedy Costa; Antônio Felix da Silva Filho; Maira Galdino da Rocha Pitta; Moacyr Jesus Barreto de Melo Rêgo; Ivone Antônia de Souza; Patrícia Maria Guedes Paiva; Thiago Henrique Napoleão
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-02-17

4.  Novel hybrid antiviral VTRRT-13V2.1 against SARS-CoV2 main protease: retro-combinatorial synthesis and molecular dynamics analysis.

Authors:  Vishvanath Tiwari
Journal:  Heliyon       Date:  2020-09-30

5.  Composite P(3HB-3HV)-CS Spheres for Enhanced Antibiotic Efficiency.

Authors:  Oana Gherasim; Alexandru Mihai Grumezescu; Anton Ficai; Valentina Grumezescu; Alina Maria Holban; Bianca Gălățeanu; Ariana Hudiță
Journal:  Polymers (Basel)       Date:  2021-03-23       Impact factor: 4.329

6.  De novo design, retrosynthetic analysis and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2.

Authors:  Vishvanath Tiwari
Journal:  Biol Open       Date:  2020-10-15       Impact factor: 2.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.